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Abstract
Background
Nephrotoxicity of intravenous (IV) colistin has impeded its clinical use; aerosolized (AS)
colistin may be an alternative, but safety data are lacking. Therefore, this study aimed to
evaluate the incidence of acute kidney injury (AKI) and risk factors associated with IV and
AS colistin administration.
Methods
A retrospective study was performed in a tertiary referral hospital. Data were collected
before and after colistin administration between October 2012 and April 2016. Exclusion cri-
teria were as follows: age less than 18 years, previous colistin administration, concurrent
use of IV and AS colistin, dialysis before colistin use, and colistin use for less than 3 days.
We compared AKI incidence following administration of IV versus AS colistin and analyzed
risk factors for colistin-associated nephrotoxicity.
Results
A total of 464 patients were enrolled (n = 311, IV group; n = 153, AS group). Incidence of
AKI was significantly higher in the IV group (IV vs AS, 20.26% vs 7.84%, p-value < 0.001).
Duration of colistin use (OR 1.033, 95% CI 1.009–1.058, p-value 0.008) and presence of
chronic kidney disease (OR 2.710, 95% CI 1.348–5.448, p-value 0.005) were associated
with nephrotoxicity. There were no significant risk factors associated with AS colistin.
Conclusions
Although AS colistin was not associated with any significant risk factors for nephrotoxicity,
duration of colistin use and baseline kidney function may affect AS colistin-associated
nephrotoxicity.
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Introduction
Recently, incidence of infections with multidrug-resistant gram-negative (MDR G (-)) patho-
gens, such as Pseudomonas aeruginosa, Acinetobacter baumannii, Klebsiella pneumoniae, and
Enterobacter, has risen. These infections represent a threat to public health because these
gram-negative bacteria are resistant to commonly used antibiotics such as antipseudomonal
penicillins and cephalosporins, aminoglycosides, tetracyclines, fluoroquinolones, and carbape-
nems [1]. Elimination of the pathogen is necessary for successful treatment. Therefore, the
emergence of MDR G (-) pathogens has encouraged clinicians to review existing antibiotics
for alternative treatment options, of which colistin is a potential alternative for treatment of
MDR G (-) pathogens [1–3].
Colistin is a mixture of the cyclic polypeptides colistin A and B and is effective against
gram-negative bacilli. Colistin was first used clinically in the 1960s. However, use of colistin
has declined since the 1970s due to adverse side effects and development of less-toxic antibiot-
ics [4,5]. The major adverse drug reaction resulting from colistin use is nephrotoxicity, which
is the main obstacle to its widespread use [5,6]. Many peer-reviewed studies have examined
colistin-induced nephrotoxicity.[6–12]. Colistin induces nephrotoxicity through increased
tubular epithelial cell membrane permeability. As a result, cations, anions, and water are able
to enter cells more freely, leading to cell swelling and lysis. Finally, acute tubular necrosis
occurs through increased serum creatinine (SCr) level and decreased creatinine clearance
(CLCr) [13]. Nephrotoxicity may be linked to changes in transepithelial conductance in epi-
thelial cells, as demonstrated in vitro in rabbit bladder epithelium [13]. The prevalence of the
reported nephrotoxicity varied between 10.9% and 45% [6]. We attributed this wide range to
the different definitions of nephrotoxicity applied in each study and inclusion of patients with
different characteristics [7].
Colistin can be administered via two routes, IV or aerosolized (AS). IV colistin treatment of
pulmonary infection is ineffective owing to low penetration of IV colistin into the lung paren-
chyma [14]. As a result, AS colistin has emerged as an alternative therapy to increase efficacy
and avoid systemic toxicity in treatment of lung infections [15,16]. Subsequently, meta-analy-
ses, systemic reviews, and retrospective studies have been conducted to compare the efficacies
of IV and AS colistin. These studies reported that efficacy of AS colistin was comparable to IV
colistin [17–20]. AS colistin is theoretically regarded to be safer because colistin-associated
nephrotoxicity is known to be dose-dependent and associated with tubular necrosis through
an increase in tubular epithelial cell membrane permeability; furthermore, large amounts of
AS colistin is not delivered to the systemic blood [6,21]. Some studies have shown that nebu-
lized colistin induces less nephrotoxicity than IV colistin. One recent retrospective study
demonstrated that nephrotoxicity was less common in AS than in IV colistin monotherapy
[20]. In addition, other studies also showed less nephrotoxicity resulting from AS colistin
monotherapy. However, nephrotoxicity resulting from AS colistin was not well-characterized
because of a small patient sample size [18,19]. Moreover, combination treatment with AS and
IV colistin showed similar nephrotoxicity to IV colistin monotherapy [18,22–25]. Based on
our review, risk of nephrotoxicity resulting from AS colistin treatment is low. However, factors
that may influence nephrotoxicity resulting from AS colistin use are not well-characterized.
The aim of this study was to evaluate the incidence of acute kidney injury (AKI) and risk fac-
tors of AKI associated with IV or AS colistin monotherapy. This study will provide more com-
plete information regarding factors that should be considered to reduce colistin-associated
toxicity.
Risk factors of intravenous and aerosolized colistin
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Materials and methods
Subjects
This single-center retrospective study was conducted in Severance Hospital, Seoul, South
Korea. In total, 893 patients who were administered IV or AS colistin between October 2012
and April 2016 were evaluated. Subjects who were outpatients, younger than 18 years, had
been previously administered colistin, used colistin for less than 3 days, received dialysis before
colistin use, and who used IV and AS colistin concurrently were excluded from the study.
According to the product label in Korea, 3 million units (MU) equals 100 mg. In Korea, the
recommended dose is 2.5–5 mg/kg/d (75,000–150,000 units/kg/d) of IV colistin in 2–4 doses
without a loading dose, and dose can be adjusted according to kidney function. Weight is
based on actual body weight (ABW) except for obese patients, who use ideal body weight
(IBW) for dosing [26]. Different from IV colistin, AS colistin is used as an off-label drug, thus,
dosage range varies because clinicians usually rely on their experience to determine the dose.
However, 75 mg (2.25 MU) of AS colistin was usually administered 3 to 4 times per day. The
study protocol was approved by the institutional review board (IRB) of Yonsei University
Health System (Seoul, South Korea, IRB No.4-2016-0490) and all data provided form hospital
were anonymized and informed consent was waived by IRB.
Data collection
The following patient information was gathered from electronic medical records (EMRs): age,
sex, actual body weight (ABW), height, colistin administration route, colistin dose, duration of
colistin use, SCr before and after colistin administration, blood urea nitrogen (BUN) before
and after colistin administration, dialysis record after colistin use, underlying diseases (hyper-
tension, diabetes mellitus, and chronic kidney disease), infected pathogens, APACHE2 (Acute
Physiology and Chronic Health Evaluation) score, and other concomitant nephrotoxins
[7,27]. If the EMRs contained several data points on the first or last day of colistin administra-
tion, the mean value was used; if records were not available on the first or last day of colistin
administration, the nearest record was used. APACHE2 score was calculated only in ICU
patients.
Definitions
IBW was calculated by using the Devine formula for height of more than 5 feet (for men, 50 kg
+ 2.3 kg for each inch over 5 feet; for women, 45.5 kg + 2.3 kg for each inch over 5 feet). IBW
was calculated by the equations of less than 5 feet (for men, 50 kg -2.3 kg for each inch less 5
feet; for women, 45.5 kg-2.3kg for each inch less 5 feet [26]. Accumulation dose, daily dose,
daily dose per ABW, and daily dose per IBW were calculated to determine if these doses could
affect nephrotoxicity.
The estimated glomerular filtration rate (eGFR) was calculated to assess kidney function by
using the abbreviated MDRD study equation [eGFR = 175 × SCr-1.154 × Age-0.203 × Sex (0.742
for female, 1 for male) × Race (1.21 for black, 1 for nonblack)] [28].
Nephrotoxicity by colistin was originally defined using the KDIGO 2012 guideline [29].
However, to reflect clinical situations that SCr is elevated, but kidney function is normal, neph-
rotoxicity was defined by SCr exceeding 2 mg/dL (176.8 μmol/L) after colistin use when
patients’ baseline eGFR was higher than 60 mL/min/1.73 m2 [30]. Patients with baseline eGFR
less than 60 mL/min/1.73 m2, and elevated SCr by more than 1.5 times control, or 0.3 mg/dL,
were considered to have colistin-induced nephrotoxicity per KDIGO 2012 guideline [29]; All
subjects that underwent dialysis after colistin use were also considered to have nephrotoxicity.
Risk factors of intravenous and aerosolized colistin
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Statistical analysis
Statistical analyses were performed using SPSS ver. 23 (IBM corporation, Armonk, New York,
U.S.). All tests were two-sided and the significance level was set at 0.05 (α = 0.05). Continuous
variables were presented as mean and standard deviation (SD), while categorical variables
were presented as number (n) and proportion (%). Nephrotoxicity was evaluated based on
AKI incidences resulting from IV or AS colistin administration, and the risk factors for IV or
AS colistin-associated nephrotoxicity were analyzed. An independent t-test was used for con-
tinuous variables and Fisher’s exact test was used for categorical variables. Binary multivariate
logistic regression was used to evaluate risk factors for colistin-associated nephrotoxicity.
Covariates that showed statistical significance in univariate logistic regression were selected
for multivariate logistic regression.
Results
Patient characteristics
A total of 893 subjects were screened. In total, 385 subjects were excluded for the following rea-
sons (Fig 1): outpatient status (n = 3), age less than 18 years (n = 147), previous use of colistin
or concurrent use of IV and AS colistin (n = 80), dialysis prior to colistin use (n = 44), and
colistin use for less than 3 days (n = 155). Thus, 464 subjects were included in the study and
were grouped as follows: 311 subjects were treated with IV colistin and 153 subjects were
treated with AS colistin. Colistin was used when other antibiotics were ineffective and culture
results were sensitive to colistin. Most patients were in sepsis. The baseline characteristics of
the patients treated with IV and AS colistin are summarized in Table 1. Most characteristics
were not significantly different except for age, type of pathogen, the number of ICU patients,
dosing, and concomitant nephrotoxins. The results showed that patients treated with IV colis-
tin were younger (IV vs AS, 63.42 vs 67.03 years; p-value 0.021), and all categories of colistin
Fig 1. Study design.
https://doi.org/10.1371/journal.pone.0207588.g001
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Table 1. Baseline patient’s characteristics.
IV
(n = 311)
AS
(n = 153)
p-valuea
Age (year) 63.42 (16.43) 67.03 (14.37) 0.021
Sex Man Woman Man Woman 0.302
198 (63.67) 113 (36.33) 105 (68.63) 48 (31.37)
Height (cm) 162.72 (9.92) 164.45 (8.56) 0.065
ABW (kg) 60.67 (12.55) 61.89 (11.62) 0.313
IBW (kg) 57.53 (10.44) 59.34 (9.53) 0.070
Duration of colistin use (day) 13.07 (12.93) 12.61 (9.80) 0.702
Baseline SCr (mg/dL) 1.00 (1.03) 0.85 (0.88) 0.116
Baseline eGFR (mL/min/1.73 m2) 129.24 (99.90) 142.40 (92.08) 0.172
Baseline BUN (mg/dL) 32.62 (23.30) 29.41 (18.75) 0.111
Underlying diseases (%)
Hypertension 192 (61.74) 101 (66.01) 0.416
Diabetes mellitus 107 (34.41) 57 (37.25) 0.606
Chronic kidney disease 78 (25.08) 27 (17.65) 0.077
Type of pathogens (%) 0.009
Acinetobacter baumannii 146 (46.95) 64 (41.83)
Pseudomonas aeruginosa 76 (24.44) 28 (18.30)
Staphylococcus aureus 50 (16.08) 31 (20.26)
Enterococcus 18 (5.79) 6 (3.92)
Klebsiella pneumoniae 5 (1.61) 3 (1.96)
Other gram-negative pathogens 14 (4.50) 18 (11.76)
Unknown 2 (0.64) 3 (1.96)
ICU patients 136 (43.73) 97 (63.40) < 0.001
APACHE2 scoreb 24.55 (8.56) 24.49 (8.17) 0.960
Accumulated dose (mg) 4388.03 (4714.22) 3112.85 (3065.82) 0.001
Daily dose (mg) 366.27 (174.77) 240.71 (93.59) <0.001
Daily dose per ABW (mg/kg/d) 6.30 (3.62) 4.02 (1.74) <0.001
Daily dose per IBW (mg/kg/d) 6.81 (6.29) 4.19 (1.86) <0.001
Nephrotoxins (%)
Amphotericin B (Liposomal) 31 (9.97) 7 (4.58) 0.049
Amphotericin B (Deoxycholate) 46 (14.79) 15 (9.80) 0.146
NSAIDs 79 (25.40) 43 (28.10) 0.575
ACE inhibitors 6 (1.93) 1 (0.65) 0.434
ARBs 21 (6.75) 11 (7.19) 0.848
Vasopressor 228 (73.31) 108 (70.59) 0.581
Diuretics 57 (18.33) 53 (34.64) <0.001
Aminoglycosides 4 (1.29) 3 (1.96) 0.689
Rifampin 18 (5.79) 10 (6.54) 0.836
Vancomycin 93 (29.90) 22 (14.38) <0.001
Cyclosporine 5 (1.61) 0 (0.00) 0.176
Tacrolimus 18 (5.79) 20 (13.07) 0.011
Radiocontrast 29 (9.32) 9 (5.88) 0.279
Data are presented as mean and SD for continuous data and number of subjects and proportion for categorical data. Categorical data are sex, underlying diseases, site of
infection, type of pathogens, ICU patients, and nephrotoxic drugs. ABW, actual body weight; IBW, ideal body weights; SCr, serum creatinine; BUN, blood urea
nitrogen; eGFR, estimated glomerular filtration rate; NSAIDs, non-steroidal anti-inflammatory drugs; ACE inhibitors, acetylcholinesterase inhibitors; ARBs,
angiotensin receptor blockers
ap-value was calculated by independent t-test for continuous data and Fisher’s exact test for categorical data using SPSS ver.23 (IBM corporation, Armonk, New York,
U.S.)
bAPACHE2 score was calculated only in ICU patients.
https://doi.org/10.1371/journal.pone.0207588.t001
Risk factors of intravenous and aerosolized colistin
PLOS ONE | https://doi.org/10.1371/journal.pone.0207588 November 21, 2018 5 / 13
doses (accumulated dose, daily dose, daily dose per ABW, and daily dose per IBW) were higher
in the IV group. In the case of concomitant nephrotoxins, liposomal amphotericin B (IV vs
AS, 9.97% vs 4.58%; p-value 0.049) and vancomycin (IV vs AS, 29.90% vs 14.38%; p-value <
0.001) were more frequently used in the IV group. In contrast, diuretics (IV vs AS, 18.33% vs
34.64%; p-value < 0.001) and tacrolimus (IV vs AS, 5.79% vs 13.07%; p-value 0.011) were
more commonly used in the AS group. Cyclosporine was not used in the AS group. APACHE2
score was calculated after ICU admission, and AS colistin was used more in ICU patients than
IV colistin (IV vs AS, 43.73% vs 63.40%; p-value < 0.001). However, APACHE2 score did not
differ between the two groups.
Kidney function assessment
AKI developed in 63 (20.26%) of the 311 patients in the IV group and 12 (7.84%) of the 153
patients in the AS group (Fig 2). AKI was significantly more frequent in the IV group than in
the AS group (p-value < 0.001).
Risk factors for IV and AS colistin-associated nephrotoxicity
Binary univariate and multivariate logistic regression analyses were performed to determine
the risk factors for IV and AS colistin-associated nephrotoxicity (Tables 2 and 3). Age, sex,
colistin administration route, height, ABW, IBW, duration of colistin use, baseline SCr, base-
line eGFR, baseline BUN, accumulated dose, daily dose, daily dose per ABW, daily dose per
IBW, hypertension, diabetes mellitus, chronic kidney disease (CKD), number of nephrotoxins,
and each individual nephrotoxin were analyzed as the risk factors.
In the AS group, there were no significant nephrotoxicity-associated risk factors as deter-
mined by multivariate analysis. Angiotensin-converting enzyme (ACE) inhibitors, angiotensin
receptor blockers (ARBs), and cyclosporine were not analyzed due to the low number of cases
of use concurrent with colistin. However, duration of colistin use, baseline SCr, baseline eGFR,
and baseline BUN were determined to be significant risk factors using univariate analysis.
Fig 2. Acute kidney injury incidence due to intravenous (IV) and aerosolized (AS) colistin. Data represent the
proportion in each group (number of AKI subjects/total number of subjects); AKI, acute kidney injury; ap-value was
lower than 0.001 and was calculated by Fisher’s exact test for categorical data using SPSS ver.23 (IBM corporation,
Armonk, New York, U.S.).
https://doi.org/10.1371/journal.pone.0207588.g002
Risk factors of intravenous and aerosolized colistin
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Multivariate analysis of administration of IV colistin showed that longer duration of colistin
use and presence of CKD are associated with nephrotoxicity. The odds ratio (OR) of duration
of colistin use was 1.033 [95% confidence interval (CI) 1.009–1.058; p-value 0.008], and the
OR of CKD was high at 2.710 (95% CI, 1.348–5.448; p-value 0.005).
Comparison of AKI and non-AKI patients
Between AKI and non-AKI patients, duration of colistin use, kidney function, and accumu-
lated dose were significantly different. In total subjects, the AKI group used colistin for one
week longer than the non-AKI group (18.77 ± 18.92 vs 11.79 ± 9.75 days, p-value < 0.001).
Factors associated with kidney function were worse in the AKI group (AKI vs non-AKI;
Table 2. Univariate and multivariate analyses of risk factors for intravenous colistin-associated nephrotoxicity.
Characteristics Univariate analysis Multivariate analysis
OR (95% CI) p-valuea OR (95% CI) p-valuea
Age 1.004 (0.987–1.021) 0.676
Sex 0.530 (0.285–0.987) 0.045
Height 1.022 (0.992–1.053) 0.149
ABW 1.021 (0.999–1.044) 0.065
IBW 1.025 (0.996–1.054) 0.088
Duration of colistin use 1.039 (1.016–1.062) 0.001 1.033 (1.009–1.058) 0.008
Baseline SCr 1.779 (1.336–2.368) <0.001
Baseline eGFR 0.992 (0.988–0.996) <0.001
Baseline BUN 1.016 (1.005–1.027) 0.004
Accumulated dose 1.000 (1.000–1.000) 0.029
Daily dose 0.998 (0.996–0.999) 0.008
Daily dose per ABW 0.827 (0.738–0.927) 0.001
Daily dose per IBW 0.850 (0.766–0.943) 0.002
Hypertension 2.570 (1.348–4.899) 0.004
Diabetes mellitus 0.942 (0.524–1.691) 0.841
Chronic kidney disease 4.533 (2.516–8.166) <0.001 2.710 (1.348–5.448) 0.005
Number of nephrotoxic drugs 1.180 (0.951–1.463) 0.133
Amphotericin B (Liposomal) 0.736 (0.271–2.000) 0.548
Amphotericin B (Deoxycholate) 0.670 (0.284–1.578) 0.359
NSAIDs 2.159 (1.197–3.896) 0.011
ACE inhibitors 2.000 (0.358–11.174) 0.430
ARBs 0.921 (0.299–2.841) 0.886
Vasopressor 0.981 (0.526–1.831) 0.953
Diuretics 1.205 (0.604–2.407) 0.596
Aminoglycosidesb -
Rifampin 0.777 (0.218–2.770) 0.697
Vancomycin 1.115 (0.614–2.025) 0.721
Cyclosporine 2.678 (0.438–16.378) 0.286
Tacrolimus 2.070 (0.745–5.751) 0.163
Radiocontrast 2.274 (1.000–5.173) 0.050
OR, odds ratio; CI, confidence interval; ABW, actual body weight; IBW, ideal body weights; SCr, serum creatinine; eGFR, estimated glomerular filtration rate; BUN,
blood urea nitrogen; NSAIDs, non-steroidal anti-inflammatory drugs; ACE inhibitors, acetylcholinesterase inhibitors; ARBs, angiotensin receptor blockers
ap-value was calculated by logistic regression using SPSS ver.23 (IBM corporation, Armonk, New York, U.S.)
bAminoglycosides was not analyzed due to very low number of cases.
https://doi.org/10.1371/journal.pone.0207588.t002
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baseline SCr, 1.65 ± 1.56 vs 0.82 ± 0.76 mg/dL, p-value < 0.001; baseline eGFR 85.03 ± 75.14
vs 142.94 ± 98.60 mL/min/1.73 m2, p-value <0.001; baseline BUN 41.69 ± 27.41 vs 29.61 ±
20.18 mg/dL, p-value < 0.001) and more common in CKD patients [35/75 (46.7%) vs 70/389
(18.0%), p-value <0.001]. There was no difference in the dose between the two groups, but the
accumulated dose was higher in the AKI group because colistin was used for a longer duration
(5480.71 ± 6049.72 vs 3675.81 ± 3789.46 mg, p-value = 0.015). Comparison of AKI and non-
AKI patients treated with AS colistin yielded similar results to the comparison between AKI
and non-AKI without AS colistin (Table 4). The comparisons in common were duration of
colistin was longer by one week (18.83 ± 8.31 vs 12.09 ± 9.76 days, p-value = 0.022 in AS colis-
tin), kidney function related factors were worse, and accumulated dose was higher in the AKI
group treated with AS colistin.
Table 3. Univariate and multivariate analyses of risk factors for aerosolized colistin-associated nephrotoxicity.
Characteristics Univariate analysis Multivariate analysis
OR (95% CI) p-valuea OR (95% CI) p-valuea
Age 0.988 (0.950–1.028) 0.552
Sex 0.711 (0.184–2.753) 0.622
Height 1.000 (0.934–1.072) 0.992
ABW 1.024 (0.974–1.076) 0.346
IBW 1.004 (0.943–1.069) 0.900
Duration of colistin use 1.047 (1.003–1.094) 0.038
Baseline SCr 2.723 (1.475–5.026) 0.001
Baseline eGFR 0.985 (0.973–0.997) 0.011
Baseline BUN 1.042 (1.016–1.069) 0.001
Accumulated dose 1.000 (1.000–1.000) 0.070
Daily dose 1.004 (0.999–1.010) 0.138
Daily dose per ABW 1.178 (0.871–1.592) 0.287
Daily dose per IBW 1.205 (0.913–1.590) 0.187
Hypertension 1.032 (0.296–3.602) 0.960
Diabetes mellitus 1.223 (0.369–4.049) 0.742
Chronic kidney disease 1.625 (0.409–6.449) 0.490
Number of nephrotoxic drugs 1.163 (0.706–1.914) 0.553
Amphotericin B (Liposomal) 5.440 (0.935–31.654) 0.059
Amphotericin B (Deoxycholate) 1.969 (0.389–9.969) 0.413
NSAIDs 0.488 (0.102–2.324) 0.367
ACE inhibitorsb -
ARBsb -
Vasopressor 2.194 (0.461–10.440) 0.324
Diuretics 0.607 (0.157–2.344) 0.469
Aminoglycosides 6.318 (0.530–75.275) 0.145
Rifampin 1.333 (0.154–11.511) 0.794
Vancomycin 1.210 (0.247–5.935) 0.814
Cyclosporineb -
Tacrolimus 1.367 (0.277–6.747) 0.701
Radiocontrast 1.511 (0.173–13.209) 0.709
OR, odds ratio; CI, confidence interval; ABW, actual body weight; IBW, ideal body weights; SCr, serum creatinine; eGFR, estimated glomerular filtration rate; BUN,
blood urea nitrogen; NSAIDs, non-steroidal anti-inflammatory drugs; ACE inhibitors, acetylcholinesterase inhibitors; ARBs, angiotensin receptor blockers
ap-value was calculated by logistic regression using SPSS ver.23 (IBM corporation, Armonk, New York, U.S.)
bACE inhibitors, ARBs, and cyclosporine and were not analyzed due to very low number of cases.
https://doi.org/10.1371/journal.pone.0207588.t003
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Discussion
Use of AS colistin for improved efficacy and reduction of systemic toxicity in pulmonary infec-
tion has increased. However, studies of nephrotoxicity resulting from AS colistin treatment
are sparse, and those that were reported contained only a small number of patients [15,16,
18,19]. In one study, AS colistin monotherapy resulted in less nephrotoxicity than IV colistin
monotherapy [20]. However, nephrotoxicity associated factors were not evaluated. In our
study, the theoretical safety of AS colistin with regard to nephrotoxicity was evaluated and
compared to nephrotoxicity resulting from IV colistin treatment. In addition, we attempted to
elucidate risk factors that can affect AS or IV colistin-induced nephrotoxicity.
In this study, we defined nephrotoxicity as follows: SCr elevated more than 1.5 times or 0.3
mg/dL in patients having baseline eGFR less than 60 mL/min/1.73 m2 (compared to the con-
trol), according to KDIGO 2012 guidelines [29]; SCr exceeding 2 mg/dL (176.8 μmol/L) after
colistin use in patients having baseline eGFR higher than 60 mL/min/1.73 m2 [30]. We defined
patients with nephrotoxicity as having baseline eGFR higher than 60 mL/min/1.73 m2 because
factors that affect renal function could not be precisely controlled because this was a retrospec-
tive study. In addition, we felt that simply increasing the SCr threshold by 50% in patients with
normal kidney function would be unlikely to be representative of true nephrotoxicity. Despite
a 1.5-times increase in SCr in the normal kidney function group, many patients presented
with low Scr. Individuals with low SCr were not considered to have impaired renal function
and were not treated in clinical practice. According to these standards, the results of our study
demonstrated that nephrotoxicity occurred twice as frequently with IV versus AS colistin
treatment (20.26% vs 7.84%; p-value < 0.001, Fig 2). Few studies have compared nephrotoxi-
city between IV colistin monotherapy and AS colistin monotherapy. One retrospective obser-
vational study showed no nephrotoxic adverse events with AS colistin treatment. However,
only six patients received AS colistin [18]. In another retrospective study, nephrotoxicity inci-
dence was 4 times higher with IV colistin compared to AS colistin[20]. These studies agree
with the results of our retrospective study.
Table 4. Comparison of AKI and non-AKI patients treated with AS colistin.
AKI
(n = 12)
Non-AKI
(n = 141)
p-valuea
Duration of colistin use (day) 18.83 (8.31) 12.09 (9.76) 0.022
Baseline SCr (mg/dL) 2.10 (2.11) 0.74 (0.59) 0.047
Baseline eGFR (mL/min/1.73 m2) 74.80 (75.62) 148.15 (91.28) 0.008
Baseline BUN (mg/dL) 48.13 (28.53) 27.82 (16.88) 0.032
Chronic kidney disease 3 (25.00) 24 (17.00) 0.445
Accumulated dose (mg) 4783.33 (1810.81) 2970.68 (3112.52) 0.049
Daily dose (mg) 279.81 (113.32) 237.38 (91.42) 0.132
Daily dose per ABW (mg/kg/d) 4.54 (2.41) 3.98 (1.68) 0.285
Daily dose per IBW (mg/kg/d) 4.87 (2.49) 4.13 (1.79) 0.183
APACHE2 scoreb 26.29 (6.92) 24.36 (8.28) 0.550
Data present mean (SD) for continuous data and number of subjects (proportion) for categorical data. Categorical
data are chronic kidney disease
ap-value was calculated by independent t-test for continuous data and Fisher’s exact test for categorical data using
SPSS ver.23 (IBM corporation, Armonk, New York, U.S.)
bOnly ICU patients were calculated APACHE2 score. The number of ICU patients with AKI was 7, and the number
of ICU patients with non-AKI was 90.
https://doi.org/10.1371/journal.pone.0207588.t004
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In the multivariate analyses performed to determine risk factors for AS colistin-associated
nephrotoxicity, no significant risk factors were identified. However, duration of colistin use,
baseline SCr, baseline eGFR, and baseline BUN were associated with nephrotoxicity resulting
from AS colistin treatment as determined by univariate analyses (Table 3). Similarly, these fac-
tors were also significantly associated with nephrotoxicity in the univariate analysis of IV colis-
tin. This indicates that duration of colistin use and baseline kidney function may be associated
with colistin-induced nephrotoxicity.
IV colistin-associated nephrotoxicity risk may increase with duration of colistin use. A sec-
ond risk factor for IV colistin-associated nephrotoxicity was the presence of CKD. The OR of
CKD was high at 2.710 (range, 1.348–5.448), meaning that patients with CKD have a high risk
of nephrotoxicity. As such, colistin should be used with caution in CKD patients. Contrary to
our findings, previous studies have described old age, longer duration of colistin use, diabetes
mellitus, high dose per IBW, and septic shock as risk factors [10,31,32].
Several studies have examined association of IV colistin-associated AKI with nephrotoxins.
Use of vancomycin, glycopeptides, NSAIDs, loop diuretics, and rifampin were reported to
induce IV colistin-associated AKI [7,10,31–33]. Furthermore, co-administration of more than
three nephrotoxins was reported to increase the risk of nephrotoxicity [24]. However, an
increase in the number of nephrotoxins did not increase risk in our study. However, univariate
analysis showed a significant increase in IV colistin-associated nephrotoxicity with co-admin-
istration of NSAIDS. Thus, additional studies on nephrotoxicity resulting from co-administra-
tion of NSAIDs and colistin are needed to clarify this relationship.
Several studies have examined dose-dependence of IV colistin-induced nephrotoxicity.
Kwon et al. [34] reported that dose per IBW was related to nephrotoxicity risk in patients
administered IV colistin. Lee et al. [7] reported that dose per IBW was a risk factor only in
patients with impaired kidney function. Two other studies found that use of more than 5 mg/
kg/day (IBW) IV colistin increased nephrotoxicity risk [10,32]. However, dose was not related
to colistin-associated nephrotoxicity in our study. Additionally, old age, prolonged colistin
administration, hypoalbuminemia, low serum albumin level, high Charlson Comorbidity
Index, and the presence of septic shock were reported to be related to nephrotoxicity
[7,8,31,32,34].
Comparison of the AKI group and non-AKI group showed that the AKI group used colistin
for one week longer. From these results, it could be inferred that duration of colistin use affects
nephrotoxicity. Accumulated dose is also significantly higher in the AKI group, but this may
be due to the longer use of colistin in AKI. These results showed the same trend with AS colis-
tin administration (Table 4). Colistin is not commonly used in early phases of treatment.
Colistin is used when other antibiotics have failed or colistin is suitable based on a pathogen
susceptibility test. It is possible that colistin was used in many cases because it was the only
alternative. As such, it is possible that colistin was used for long periods of time despite symp-
toms of nephrotoxicity because there are no other viable options or treatment.
Our study has some limitations that merit discussion. As this was a retrospective study,
inaccurate patient information may have been provided. If data were missing, data collected
most closely in time to the missing data were used. Furthermore, the mean value was used if
there were multiple values obtained for the same factor on the same day. In addition, Patient
clinical status was not evaluated using an APACHE II score, which would have been helpful in
assessing kidney function and risk of AKI. Despite these limitations, this study, to our knowl-
edge, is the first to attempt to determine risk factors associated AS colistin-induced nephrotox-
icity. Furthermore, this is the first study to evaluate nephrotoxicity risks between IV and AS
colistin treatment in a large number of patients.
Risk factors of intravenous and aerosolized colistin
PLOS ONE | https://doi.org/10.1371/journal.pone.0207588 November 21, 2018 10 / 13
Conclusion
From the analysis, duration of colistin use and baseline kidney function may be associated
with AS colistin-associated nephrotoxicity. Therefore, to reduce nephrotoxicity, short term
use of AS colistin and evaluation of baseline kidney function prior to treatment are
recommended.
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